The largest holder of Eli Lilly and Company stock is Lilly Endowment, Inc., with 90.4 million shares (9.60% of the company), worth about $105.00 billion as of September 25, 2026. The 10 largest holders together own 49.1%.
In Q2 2026, 4,881 institutional holdings reports listed shares worth $946.00 billion.
Insiders reported 129 transactions in the last two years: 30 sales worth $2.31 billion and 8 purchases. The newest one on file is from September 21, 2026 (Sulzberger Gabrielle, Director).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through September 21, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Lilly Endowment, Inc. | 90.4 million | 9.60% | $105.0B |
| Lilly Endowment, Inc. | 90.4 million | 9.60% | $105.0B |
| Vanguard Capital Management LLC | 53.5 million | 5.69% | $61.9B |
| PNC Wealth Management LLC | 51.1 million | 5.43% | $59.1B |
| BlackRock Advisors LLC | 50.4 million | 5.35% | $58.3B |
| State Street Corporation | 36.2 million | 3.85% | $41.9B |
| Fidelity Management & Research Co. LLC | 28.4 million | 3.02% | $32.9B |
| Capital Research & Management Co. (Global Investors) | 20.9 million | 2.22% | $24.1B |
| Vanguard Portfolio Management LLC | 20.9 million | 2.22% | $24.1B |
| Geode Capital Management LLC | 20.3 million | 2.16% | $23.5B |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 4,881 | – | $946.0B |
| Q1 2026 | 4,610 | 778.0 million | $713.0B |
| Q4 2025 | 4,683 | 795.0 million | $847.0B |
| Q3 2025 | 4,161 | 777.0 million | $592.0B |
| Q2 2025 | 4,157 | 789.0 million | $614.0B |
| Q1 2025 | 4,145 | 838.0 million | $691.0B |
| Q4 2024 | 4,114 | 783.0 million | $604.0B |
| Q3 2024 | 3,863 | 811.0 million | $705.0B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Sulzberger Gabrielle | Sep 21, 2026 | Director | Stock Award(Grant) at price 1164.89 per share. | $4,958 |
| Luciano Juan R | Sep 21, 2026 | Director | Stock Award(Grant) at price 1164.89 per share. | $15,917 |
| Alvarez Ralph | Sep 21, 2026 | Director | Stock Award(Grant) at price 1164.89 per share. | $12,417 |
| Fyrwald J. Erik | Sep 21, 2026 | Director | Stock Award(Grant) at price 1164.89 per share. | $9,917 |
| Seymour Melissa | Sep 9, 2026 | Officer | Stock Gift at price 0.00 per share. | – |
| Hernandez Edgardo | Sep 2, 2026 | Officer | Stock Gift at price 0.00 per share. | – |
| Dozier Eric | Sep 2, 2026 | Officer | Stock Gift at price 0.00 per share. | – |
| Sulzberger Gabrielle | Aug 17, 2026 | Director | Stock Award(Grant) at price 1183.16 per share. | $4,958 |
| Luciano Juan R | Aug 17, 2026 | Director | Stock Award(Grant) at price 1183.16 per share. | $15,917 |
| Jonsson Patrik | Aug 17, 2026 | Officer | Sale at price 1175.10 per share. | $7.6M |
| Alvarez Ralph | Aug 17, 2026 | Director | Stock Award(Grant) at price 1183.16 per share. | $12,417 |
| Fyrwald J. Erik | Aug 17, 2026 | Director | Stock Award(Grant) at price 1183.16 per share. | $9,917 |
Newest 12 of 129 insider transactions in the last two years.
Lilly Endowment, Inc., with 9.60% of the company (as of September 25, 2026). Next: Lilly Endowment, Inc. (9.60%) and Vanguard Capital Management LLC (5.69%).
4,881 institutional holdings reports listed Eli Lilly and Company shares in Q2 2026 worth $946.00 billion.
In the last two years insiders reported 30 sales and 8 purchases (129 transactions in all); the newest on file is from September 21, 2026.